Christopher Ogden - Aug 20, 2024 Form 4 Insider Report for CytomX Therapeutics, Inc. (CTMX)

Role: Chief Financial Officer
Signature: /s/ Lloyd Rowland, as Attorney-in-Fact for Christopher Ogden
Stock symbol: CTMX
Transactions as of: Aug 20, 2024
Transactions value $: -$2,439
Form type: 4
Date filed: 8/22/2024, 05:59 PM
Previous filing: Jun 14, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CTMX	Common Stock	Options Exercise	$0	+6.88K	+6.66%	$0.00	110K	Aug 20, 2024	Direct	F1, F2
transaction	CTMX	Common Stock	Sale	-$2.44K	-1.98K	-1.8%	$1.23	108K	Aug 20, 2024	Direct	F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CTMX	Performance Stock Units (PSUs)	Options Exercise	$0	-6.88K	-100%	$0.00	0	Aug 20, 2024	Common Stock	6.88K		Direct	F1, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents vesting of a Performance Stock Unit ("PSU") award initially granted on August 10, 2022.
F2	Includes 77,810 restricted stock units.
F3	The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of PSUs reported herein.
F4	Each PSU represents a contingent right to receive one share of the Issuer's Common Stock upon vesting. 50% of the PSUs vested on December 17, 2023 upon achievement of a certain performance-based milestone. In connection with the vesting reported herein, the remaining 50% of the PSUs vested upon achievement of a certain performance-based milestone.